Market research
MDC.AU Medlab Clinical Limited
AU AUD Healthcare
Latest close
Latest stored close unavailable
Test a moving-average rule with historical data.
Market facts
- Market cap
- 15M
- P/E ratio
- 0.0
- Analyst target
- 18.84
- Dividend yield
- 0.0%
- Beta
- 0.91
Profile
Instrument facts
- Exchange
- AU
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- AU000000MDC8
- Market cap
- 15M
- P/E ratio
- 0.0
- Analyst target
- 18.84
- Dividend yield
- 0.0%
- Beta
- 0.91
About
About Medlab Clinical Limited
Medlab Clinical Limited, a biotechnology company, researches, develops, and pre-commercializes pharmaceutical and nutraceutical products in Australia. Its drug candidate includes NanaBis, a buccal spray from cannabis oil extract for oncology and pain management; and NanoCBD, a buccal spray from hemp oil extract for mental health. The company also develops NanoCelle, a patented sub-micron drug delivery platform that allows passive diffusion of active pharmaceutical ingredients directly into the bloodstream through oral-buccal, sublingual, intranasal, and transdermal or topical delivery. In addition, it offers virtual clinic services. The company was founded in 2012 and is headquartered in Botany, Australia.
Research context
Medlab Clinical Limited appears in PyInvesting’s Australia Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the MDC.AU discussion.
5 years, 6 months ago
Medlab Clinical Limited is currently in a long term downtrend where the price is trading 31.8% below its 200 day moving average.
From a valuation standpoint, the stock is 93.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 17.4.
Medlab Clinical Limited's total revenue rose by 57.4% to $4M since the same quarter in the previous year.
Its net income has increased by 25.4% to $-5M since the same quarter in the previous year.
Finally, its free cash flow grew by 42.2% to $-2M since the same quarter in the previous year.
Based on the above factors, Medlab Clinical Limited gets an overall score of 4/5.